Why the study?
Does a single bolus of 7E3-Fab improve graft patency in a canine arterial eversion graft model?
Does a single bolus of 7E3-Fab improve graft patency in a canine arterial eversion graft model?
A single bolus of 7E3-Fab significantly improved 24-hour graft patency in a canine arterial eversion graft model.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of 7E3-Fab; leaves open translation from canine models to human trials.
The contribution of platelets and the vessel wall to the antithrombotic effects of a single intravenous bolus injection of 0.8 mg/kg Fab fragments of the monoclonal antiplatelet glycoprotein IIb/IIIa receptor antibody 7E3 (7E3-Fab), combined with continuous heparin anticoagulation (100 U/kg bolus and 50 U/kg per hour), was studied in a canine preparation consisting of an everted (inside out) carotid arterial segment that had been inserted into a transected femoral artery. In all 6 control dogs without antibody, persistent or transient eversion graft occlusion occurred during an initial 2-hour observation period, and 5 of the 6 grafts were occluded at 24 hours. In 6 dogs given 7E3-Fab 24 hours before receiving an everted carotid artery segment from a donor dog, cyclic occlusion and reflow occurred in all dogs, whereas the grafts were patent at the end of a 2-hour observation period in 5 of the 6 dogs (P = .056 versus control). When transferred back to the donor dogs, the patient eversion segments showed brief periods of cyclic occlusion and reflow within 2 hours in 3 of 5 dogs (P = .034 versus control), whereas all of the 5 eversion segments were patent at 24 hours (P < .005 versus control).(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Kiss et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: